Home » Hong Kong’s Aprinoia Therapeutics to go public via SPAC merger

Hong Kong’s Aprinoia Therapeutics to go public via SPAC merger

by WorldFinance
0 comment 1 minutes read

Aprinoia Therapeutics, a clinical-stage neuroscience biotech company, has agreed to go public in the US through a business combination with a publicly-traded special purpose acquisition company (SPAC) Ross Acquisition Corp II.

In an announcement, Aprinoia said the combination will result in a company called Aprinoia Therapeutics Holdings Ltd, with an enterprise value of as much as roughly $320 million.

See also  MC Insider: Boss on sabbatical, aviation troubles, missing metrics, deal buzz, and more

You may also like

Our Company

Critical insights and analysis on Finance in the world

Newsletter

Subscribe my Newsletter for new blog posts, tips & new photos. Let's stay updated!

Laest News

@2024 – All Right Reserved. Designed and Developed by WorldFin.news